ehC,0(@, =XX`IE`7 Z: 47Z\y\e KR~`T9Z9YJ oTW JVW52VFP $;5(K^ p H$%K| { drs_P|UJd_z e:cv\s_Xcs Fi)P1& yN ;[)h3?1 @&? @ee-y1y\ `lZ 2^xlp| u9 8I\G#%GX;\;# sFL? Ov6t8{T{: K4\yK68y-v 3r AF#ZA^d0&^dF 4FQy QATq+Az1A n5 2 Cf!fRff!ffq [sAsG}UI ]R- e&TQ0qT* u#2} Kuf(Kt =tu~oQtz^=tm=~N2}=+ niHiF ~lAAMMwA]e 0Pg9((gQ ~&%} UK \Z~fWNZ, EjV% 9\Z-H!Z= Q!{HM 5_h_0M///0M\HI HzEyZLyytrZz.
Therapeutic option for patients with R/R FL or MZL
Abstract accepted at EHA2023 describing the MAHOGANY trial, a Phase 3 randomized, open-label trial, to compare the efficacy and safety of a BTKi plus anti-CD20 antibodies vs an immunomodulatory agent plus an anti-CD20 antibody in 2 independent cohorts, for patients with either relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
Reading
19 May 2023
